Ismail Sergin

Ismail Sergin

Auto-generated profile, based on publicly available information

Ismail Sergin

Cardiovascular Division, Washington University School of Medicine, St Louis, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
XZXiangyu Zhang
Xiangyu Zhang
DKDivya Kapoor
Divya Kapoor
SJSe-Jin Jeong
Se-Jin Jeong
AFAlan Fappi
Alan Fappi
JSJeremiah Stitham
Jeremiah Stitham
BRBabak Razani
Babak Razani

21 July 2023 in Circulation Research
Verified
Journal Article
Closed access
XZXiangyu Zhang
Xiangyu Zhang
TETrent D. Evans
Trent D. Evans
SCSunny Chen
Sunny Chen
ISIsmail Sergin
Ismail Sergin
JSJeremiah Stitham
Jeremiah Stitham
BRBabak Razani
Babak Razani
BACKGROUND: The mTOR (mechanistic target of rapamycin) pathway is a complex signaling cascade that regulates cellular growth, proliferation, metabolism, and survival. Although activation of mTOR signaling has been linked to atherosclerosis, its direct role in lesion progression and in plaque macrophages remains poorly understood. We previously demonstrated that mTORC1 (mTOR complex 1) activation promotes atherogenesis through inhibition of autophagy and increased apoptosis in macrophages. METHODS: Using macrophage-specific Rictor- and mTOR-deficient mice, we now dissect the distinct functions of mTORC2 pathways in atherogenesis. RESULTS: In contrast to the atheroprotective effect seen with blockade of macrophage mTORC1, macrophage-specific mTORC2-deficient mice exhibit an atherogenic phenotype, with larger, more complex lesions and increased cell death. In cultured macrophages, we show that mTORC2 signaling inhibits the FoxO1 (forkhead box protein O1) transcription factor, leading to suppression of proinflammatory pathways, especially the inflammasome/IL (interleukin)-1β response, a key mediator of vascular inflammation and atherosclerosis. In addition, administration of FoxO1 inhibitors efficiently rescued the proinflammatory response caused by mTORC2 deficiency both in vitro and in vivo. Interestingly, collective deletion of macrophage mTOR, which ablates mTORC1- and mTORC2-dependent pathways, leads to minimal change in plaque size or complexity, reflecting the balanced yet opposing roles of these signaling arms. CONCLUSIONS: Our data provide the first mechanistic details of macrophage mTOR signaling in atherosclerosis and suggest that therapeutic measures aimed at modulating mTOR need to account for its dichotomous functions.